Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.61 |
| ▸ | HTR7 | P34969 | 8/20 | 0.53 |
| ▸ | HTR6 | P50406 | 6/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1383722 | 0.84 | HTR1A (0.82) | HTR1AKCNH2HTR7HTR6HTR2A | |
| SCHEMBL3869416 | 0.80 | HTR1A (0.78) | HTR1AKCNH2HTR7HTR6HTR2A | |
| SCHEMBL13532839 | 0.80 | HTR1A (0.77) | HTR1AKCNH2HTR7HTR6HTR2A | |
| SCHEMBL3869412 | 0.79 | HTR1A (0.73) | HTR1AKCNH2HTR7HTR6HTR2A | |
| SCHEMBL1382312 | 0.79 | HTR1A (1.00) | HTR1AKCNH2HTR7HTR6HTR2A | |
| SCHEMBL1383489 | 0.79 | HTR7 (0.83) | HTR1AKCNH2HTR7HTR6HTR2A | |
| SCHEMBL13532842 | 0.79 | HTR1A (0.75) | HTR1AKCNH2HTR7HTR6HTR2A | |
| SCHEMBL1383439 | 0.77 | HTR1A (0.72) | HTR1AKCNH2HTR7HTR6HTR2A | |
| SCHEMBL1384418 | 0.77 | HTR1A (1.00) | HTR1AKCNH2HTR7HTR6HTR2A | |
| SCHEMBL1382721 | 0.77 | HTR1A (0.72) | HTR1AKCNH2HTR7HTR6HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4787148-B2 | — | — | 2011-10-05 | — | — | JP | claimed |
| EP-1592425-A4 | NEW ARYLPIPERAZINYL COMPOUNDS | EPIX DELAWARE INC (US) | 2007-01-24 | — | — | EP | claimed |
| EP-1592425-A2 | NEW ARYLPIPERAZINYL COMPOUNDS | Predix Pharmaceuticals Holdings, Inc. (US) | 2005-11-09 | — | — | EP | claimed |
| WO-2004069794-A9 | NEW ARYLPIPERAZINYL COMPOUNDS | PREDIX PHARMACEUTICALS HOLDING (US) | 2004-12-09 | — | — | WO | claimed |
| US-20040220192-A1 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. | 2004-11-04 | — | — | US | claimed |
| WO-2004069794-A2 | NEW ARYLPIPERAZINYL COMPOUNDS | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2004-08-19 | — | — | WO | claimed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-7491727-B2 | Good selectivity, high affinity, metabolically stable 5-HT receptor modulators with good bioavailability, CNS penetration, and good pharmacokinetic; antiserotonine agents; central nervous system disorders; anxiolytic agents; attention deficit disorders; strokes; headaches | EPIX DELAWARE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7488731-B2 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080027066-A1 | Arylpiperazinyl Compounds | EPIX DELAWARE, INC. | 2008-01-31 | — | — | US | disclosed |
| EP-1592425-A4 | NEW ARYLPIPERAZINYL COMPOUNDS | EPIX DELAWARE INC (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20070004742-A1 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-7153858-B2 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. (US) | 2006-12-26 | — | — | US | disclosed |
| EP-1592425-A2 | NEW ARYLPIPERAZINYL COMPOUNDS | Predix Pharmaceuticals Holdings, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069794-A9 | NEW ARYLPIPERAZINYL COMPOUNDS | PREDIX PHARMACEUTICALS HOLDING (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040220192-A1 | Arylpiperazinyl compounds | EPIX DELAWARE, INC. | 2004-11-04 | — | — | US | disclosed |
| WO-2004069794-A2 | NEW ARYLPIPERAZINYL COMPOUNDS | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027066-A1 | Arylpiperazinyl Compounds | HTR5A, HTR1A, HTR2A | HTR1A 2/4885KCNH2 1225/4885HTR7 7/4885 |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | HTR1A 7/4885KCNH2 3934/4885HTR7 11/4885 |
| US-20070004742-A1 | Arylpiperazinyl compounds | HTR5A, HTR1A, HTR2A | HTR1A 2/4885KCNH2 1225/4885HTR7 7/4885 |
| US-20040220192-A1 | Arylpiperazinyl compounds | HTR5A, HTR1A, HTR2A | HTR1A 2/4885KCNH2 1225/4885HTR7 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.